3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Lymphoma
5
Lung Neoplasms
5
Multiple Myeloma
4
Lymphoma, Large-Cell, Anaplastic
4
Neuroblastoma
3
Neoplasms
2
Hematologic Neoplasms
2
Carcinoma
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Neurofibromatosis 2
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Lobular
1
Carcinoma, Large Cell
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
Advanced Cancer
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
ALK-positive NSCLC
1
ALK or ROS1-positive NSCLC
1
Interventions
Carboplatin
3
figitumumab
2
Paclitaxel
2
vandetanib
1
brigatinib
1
Temozolomide
1
Radiotherapy
1
Radiosurgery
1
Everolimus
1
Erlotinib Hydrochloride
1
Crizotinib
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Large Cell
×
Crizotinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA